Suppr超能文献

外科切除术治疗多个肝细胞癌的作用。

Role of surgical resection for multiple hepatocellular carcinomas.

机构信息

Department of Surgery, Yonsei University College of Medicine, Seoul 120-752, South Korea.

出版信息

World J Gastroenterol. 2013 Jan 21;19(3):366-74. doi: 10.3748/wjg.v19.i3.366.

Abstract

AIM

To clarify the role of surgical resection for multiple hepatocellular carcinomas (HCCs) compared to transarterial chemoembolization (TACE) and liver transplantation (LT).

METHODS

Among the HCC patients who were managed at Yonsei University Health System between January 2003 and December 2008, 160 patients who met the following criteria were retrospectively enrolled: (1) two or three radiologically diagnosed HCCs; (2) no radiologic vascular invasion; (3) Child-Pugh class A; (4) main tumor smaller than 5 cm in diameter; and (5) platelet count greater than 50 000/mm(3). Long-term outcomes were compared among the following three treatment modalities: surgical resection or combined radiofrequency ablation (RFA) (n = 36), TACE (n = 107), and LT (n = 17). The survival curves were computed using the Kaplan-Meier method and compared with a log-rank test. To identify the patients who gained a survival benefit from surgical resection, we also investigated prognostic factors for survival following surgical resection. Multivariate analyses of the prognostic factors for survival were performed using the Cox proportional hazard model.

RESULTS

The overall survival (OS) rate was significantly higher in the surgical resection group than in the TACE group (48.1% vs 28.9% at 5 years, P < 0.005). LT had the best OS rate, which was better than that of the surgical resection group, although the difference was not statistically significant (80.2% vs 48.1% at 5 years, P = 0.447). The disease-free survival rates were also significantly higher in the LT group than in the surgical resection group (88.2% vs 11.2% at 5 years, P < 0.001). Liver cirrhosis was the only significant prognostic factor for poor OS after surgical resection. Clinical liver cirrhosis rates were 55.6% (20/36) in the resection group and 93.5% (100/107) in the TACE group. There were 19 major and 17 minor resections. En bloc resection was performed in 23 patients, multi-site resection was performed in 5 patients, and combined resection with RFA was performed in 8 patients. In the TACE group, only 34 patients (31.8%) were recorded as having complete remission after primary TACE. Seventy-two patients (67.3%) were retreated with repeated TACE combined with other therapies. In patients who underwent surgical resection, the 16 patients who did not have cirrhosis had higher 5-year OS and disease-free survival rates than the 20 patients who had cirrhosis (80.8% vs 25.5% 5-year OS rate, P = 0.006; 22.2% vs 0% 5-year disease-free survival rate, P = 0.048). Surgical resection in the 20 patients who had cirrhosis did not provide any survival benefit when compared with TACE (25.5% vs 24.7% 5-year OS rate, P = 0.225). Twenty-nine of the 36 patients who underwent surgical resection experienced recurrence. Of the patients with cirrhosis, 80% (16/20) were within the Milan criteria at the time of recurrence after resection.

CONCLUSION

Among patients with two or three HCCs, no radiologic vascular invasion, and tumor diameters ≤ 5 cm, surgical resection is recommended only in those without cirrhosis.

摘要

目的

明确与经动脉化疗栓塞术(TACE)和肝移植(LT)相比,手术切除治疗多发性肝细胞癌(HCC)的作用。

方法

在 2003 年 1 月至 2008 年 12 月期间,在延世大学健康系统接受治疗的 HCC 患者中,回顾性纳入符合以下标准的 160 名患者:(1)两到三个影像学诊断的 HCC;(2)无影像学血管侵犯;(3)Child-Pugh 分级 A;(4)主肿瘤直径小于 5cm;和(5)血小板计数大于 50000/mm³。比较以下三种治疗方式的长期预后:手术切除或联合射频消融(RFA)(n=36)、TACE(n=107)和 LT(n=17)。使用 Kaplan-Meier 方法计算生存曲线,并通过对数秩检验进行比较。为了确定手术切除能使患者获益的生存人群,我们还调查了手术切除后生存的预后因素。使用 Cox 比例风险模型对生存的预后因素进行多变量分析。

结果

手术切除组的总生存率(OS)明显高于 TACE 组(5 年时分别为 48.1%和 28.9%,P<0.005)。LT 的 OS 率最好,优于手术切除组,尽管差异无统计学意义(5 年时分别为 80.2%和 48.1%,P=0.447)。LT 组的无病生存率也明显高于手术切除组(5 年时分别为 88.2%和 11.2%,P<0.001)。肝硬变是手术切除后 OS 不良的唯一显著预后因素。手术切除组的临床肝硬化发生率为 55.6%(20/36),TACE 组为 93.5%(100/107)。手术切除组中有 19 例大切除术和 17 例小切除术。23 例进行了整块切除术,5 例进行了多部位切除术,8 例进行了联合 RFA 切除术。在 TACE 组中,只有 34 名患者(31.8%)在初次 TACE 后被记录为完全缓解。72 名患者(67.3%)接受了重复 TACE 联合其他治疗的治疗。在接受手术切除的患者中,16 名无肝硬化的患者的 5 年 OS 和无病生存率均高于 20 名有肝硬化的患者(5 年 OS 率分别为 80.8%和 25.5%,P=0.006;5 年无病生存率分别为 22.2%和 0%,P=0.048)。与 TACE 相比,肝硬化患者的手术切除并未带来任何生存获益(5 年 OS 率分别为 25.5%和 24.7%,P=0.225)。36 名接受手术切除的患者中有 29 名复发。在有肝硬化的患者中,有 80%(16/20)在切除后复发时符合米兰标准。

结论

对于有两个或三个 HCC、无影像学血管侵犯和肿瘤直径≤5cm 的患者,仅建议在无肝硬化的情况下进行手术切除。

相似文献

1
Role of surgical resection for multiple hepatocellular carcinomas.
World J Gastroenterol. 2013 Jan 21;19(3):366-74. doi: 10.3748/wjg.v19.i3.366.
7
Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.
World J Gastroenterol. 2015 Apr 21;21(15):4635-43. doi: 10.3748/wjg.v21.i15.4635.

引用本文的文献

6
Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B.
Clin Mol Hepatol. 2019 Dec;25(4):390-399. doi: 10.3350/cmh.2018.0103. Epub 2019 May 31.
7
Dissecting the multinodular hepatocellular carcinoma subset: is there a survival benefit after hepatectomy?
Updates Surg. 2019 Mar;71(1):57-66. doi: 10.1007/s13304-019-00626-3. Epub 2019 Mar 9.
8
Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer-B hepatocellular carcinoma.
Oncol Lett. 2018 Nov;16(5):6383-6392. doi: 10.3892/ol.2018.9420. Epub 2018 Sep 7.
10
Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients.
Cancer Res Treat. 2019 Jan;51(1):65-72. doi: 10.4143/crt.2018.038. Epub 2018 Feb 26.

本文引用的文献

2
Chemoembolization for unresectable hepatocellular carcinoma in Japan.
Oncology. 2010 Jul;78 Suppl 1:135-41. doi: 10.1159/000315242. Epub 2010 Jul 8.
3
Clonal origin of multifocal hepatocellular carcinoma.
Cancer. 2010 Sep 1;116(17):4078-85. doi: 10.1002/cncr.25258.
7
Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
J Hepatobiliary Pancreat Surg. 2009;16(3):359-66. doi: 10.1007/s00534-009-0069-7. Epub 2009 Mar 20.
8
Liver resection improves the survival of patients with multiple hepatocellular carcinomas.
Ann Surg Oncol. 2009 Apr;16(4):848-55. doi: 10.1245/s10434-008-0282-7. Epub 2009 Jan 22.
9
Resection and liver transplantation for HCC.
J Gastroenterol. 2009;44 Suppl 19:132-5. doi: 10.1007/s00535-008-2250-1. Epub 2009 Jan 16.
10
Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B.
Dig Dis Sci. 2009 Aug;54(8):1758-63. doi: 10.1007/s10620-008-0541-2. Epub 2008 Nov 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验